[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-359871-105":59,"doc-detail-359871-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","total-neoadjuvant-chemotherapy-combined-with-pd1-blockade-and-il2-in-msspmmr-locally-advanced-rectal-cancer-short-term-results-of-a-prospective-single-arm-phase-ii-study","Total neoadjuvant chemotherapy combined with PD‑1 blockade and IL‑2 in MSS/pMMR locally advanced rectal cancer - short-term results of a prospective, single-arm phase II study","","Total neoadjuvant chemotherapy combined with PD‑1 blockade and IL‑2 was evaluated in a prospective, open-label single-arm phase II study for microsatellite stable/proficient mismatch repair (MSS/pMMR) locally advanced rectal cancer. Thirty-three patients receiving a three-week cycle of oxaliplatin, sintilimab, capecitabine, and IL‑2 underwent radical surgery after six cycles with a 100% R0 resection rate. The pathological complete response rate was 42.4% (95% CI 25.68–59.16%), and adverse events remained manageable, with 21.2% grade 3 events and no grade IV/V events or treatment-related deaths. With median follow-up of 25.5 weeks, no recurrences were observed. Immune profiling indicated activation of CD8+ T cells, NK cells, and M1 macrophages associated with pCR.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/total-neoadjuvant-chemotherapy-combined-with-pd1-blockade-and-il2-in-msspmmr-locally-advanced-rectal-cancer-short-term-results-of-a-prospective-single-arm-phase-ii-study/359871/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/total-neoadjuvant-chemotherapy-combined-with-pd1-blockade-and-il2-in-msspmmr-locally-advanced-rectal-cancer-short-term-results-of-a-prospective-single-arm-phase-ii-study/359871.png","ImageObject",300,407,{"name":92,"@type":93},"Fahsai","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What treatment regimen was used in the phase II study?","Question",{"text":112,"@type":113},"Patients received oxaliplatin, sintilimab (PD‑1 antibody), capecitabine, and IL‑2 in a three-week cycle, with response evaluations after every two cycles and surgery after six cycles.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What were the primary short-term efficacy outcomes?",{"text":117,"@type":113},"After radical surgery, all patients achieved R0 resection (100%). The pathological complete response rate was 42.4%, with remaining patients assessed as partial response.",{"name":119,"@type":110,"acceptedAnswer":120},"How did the study assess safety and what was the overall tolerability?",{"text":121,"@type":113},"No grade B/C anastomotic leakage or bowel obstruction was reported. Adverse events were manageable, with 21.2% grade 3 events and no grade IV/V events or treatment-related deaths.",{"name":123,"@type":110,"acceptedAnswer":124},"What immune changes were observed in patients achieving pCR?",{"text":125,"@type":113},"Blood and tissue analyses showed significant activation of CD8+ T cells, NK cells, and M1 macrophage subsets in the tumor microenvironment of pCR-achieving patients.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},359871,1790149290,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":19,"preview_urls":149},549768702563,"https://ap-avatar.wpscdn.com/avatar/8000c4aa63b76e948b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786536092046926083","Signal Transduction [and Targeted Therapy](and Targeted Therapy www.nature.com/sigtrans)[ www.nature.com/sigtrans](and Targeted Therapy www.nature.com/sigtrans)  \nTotal neoadjuvant chemotherapy combined with PD‑1 blockade and IL‑2 in MSS/pMMR locally advanced rectal cancer: short-term results of a prospective, single-arm phase II study  \nJunwei Tang1,2,3, Lu Wang 1,2, Sheng Yang 1,2,4, Wen Peng1,2, Yi Zhang 1,2, Yue Zhang 1,2, Kangpeng Jin1,2, Xiaowei Wang1,2,3 ✉, Yifei Feng 1,2 ✉ and Yueming Sun 1,2,3 ✉  \n\n|  | Neoadjuvant therapy has become a cornerstone in the management of locally advanced rectal cancer (LARC) . In this single-arm, open-label phase II study, we evaluated the efﬁcacy and safety of total neoadjuvant chemotherapy (TNT) using a CapOX regimen combined with a programmed cell death protein 1 (PD‑1) antibody (sintilimab) and interleukin‑2 (IL‑2) in patients with microsatellite stable (MSS)/deﬁning proﬁcient mismatch repair (pMMR) LARC. A total of 33 patients, aged 18–75 years, with rectal tumors located within 12 cm from the anal verge and staged as cT3/4N_anyM0 or cT_anyN⁺M0, were enrolled. Patients received a regimen consisting of oxaliplatin, sintilimab, capecitabine, and IL‑2 administered in a three‑week cycle, with response evaluations performed after every two cycles. Following six cycles of treatment, 33 patients underwent radical surgery, achieving a 100% R0 resection rate. The pathological complete response (pCR) rate was 42.4%(95% CI: 25.68–59.16%) while the remaining 19 patients (57.6%, 95% CI: 41.07–74.09%) were assessed as having a partial response. The tumor regression grades (TRG) were, TRG1: 3 cases (9.1%, 95% CI: 1.90–25.97%), TRG2: 14 cases (42.4%, 95% CI: 26.27–60.38%), and TRG3: 2 cases (6.1%, 95% CI: 0.73–20.37%), respectively. Surgical safety reported as no cases of grade B/C anastomotic leakage or bowel obstruction. Adverse events (AEs) were manageable, with a 21.2% incidence of grade 3 events and no grade IV/V events or treatment‑related deaths. With a median follow‑up of 25.5 weeks, no recurrences were observed. Analysis of blood and tissue samples from patients with different treatment outcomes revealed signiﬁcant activation of CD8+ T cells, NK cells, and M1 macrophage subsets in the tumor microenvironment of patients achieving pCR. These compelling data demonstrate promising efﬁcacy with a favorable safety proﬁle in MSS/pMMR LARC. These ﬁndings warrant studies to validate this regimen as a novel treatment paradigm for rectal [cancer. ClinicalTrials.gov](cancer. ClinicalTrials.gov) |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| registration: NCT06108596 . |  |  |\n|  | Signal Transduction and Targeted Therapy (2026)11:163 ; [https://doi.org/10.1038/s41392-026-02683-8](https://doi.org/10.1038/s41392-026-02683-8) |  |\n|  |  |  |\n\nINTRODUCTION  \nColorectal cancer is the third most common cancer worldwide and the second leading cause of cancer-related death.1,2 In China, the incidence of rectal cancer has been rising in recent years, with low–mid rectal cancer and locally advanced rectal cancer (LARC) being particularly prominent.3,4  \nFor patients with LARC, neoadjuvant radiotherapy or chemoradiotherapy has become the standard treatment modality; compared with adjuvant therapy, these approaches offer advantages in both oncological outcomes and quality of life.5 Immune checkpoint inhibitors (ICIs), particularly antibodies targeting programmed cell death protein 1 (PD-1) and its ligand programmed cell death ligand 1 (PD-L1), have demonstrated signiﬁcant efﬁcacy in various cancers, including colorectal cancers  \nwith high microsatellite instability (MSI-H) or deﬁcient mismatch repair (dMMR).6,7 However, in LARC most patients exhibit microsatellite stable (MSS) or proﬁcient mismatch repair (pMMR) status; thus, the efﬁcacy of ICIs as monotherapy is limite","cbCairpWocx9zORh","https://ap.wps.com/l/cbCairpWocx9zORh","pdf",1981286,"English","# Introduction\n## Study background and rationale\n# Study design and treatment approach\n## Patient eligibility and treatment regimen\n## Response evaluation and surgery outcomes\n# Results\n## Efficacy endpoints\n## Pathology and tumor regression grading\n## Safety and adverse events\n## Immune microenvironment analysis\n# Conclusion\n## Clinical implications and validation needs","[{\"question\":\"What treatment regimen was used in the phase II study?\",\"answer\":\"Patients received oxaliplatin, sintilimab (PD‑1 antibody), capecitabine, and IL‑2 in a three-week cycle, with response evaluations after every two cycles and surgery after six cycles.\"},{\"question\":\"What were the primary short-term efficacy outcomes?\",\"answer\":\"After radical surgery, all patients achieved R0 resection (100%). The pathological complete response rate was 42.4%, with remaining patients assessed as partial response.\"},{\"question\":\"How did the study assess safety and what was the overall tolerability?\",\"answer\":\"No grade B/C anastomotic leakage or bowel obstruction was reported. Adverse events were manageable, with 21.2% grade 3 events and no grade IV/V events or treatment-related deaths.\"},{\"question\":\"What immune changes were observed in patients achieving pCR?\",\"answer\":\"Blood and tissue analyses showed significant activation of CD8+ T cells, NK cells, and M1 macrophage subsets in the tumor microenvironment of pCR-achieving patients.\"}]","Total neoadjuvant chemotherapy combined with PD‑1 blockade and IL‑2 in MSS/pMMR locally advanced rectal cancer - short-term results of a prospective, single-arm phase II study | PDF",1790138075,23,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/442f32aa750ee3af194a4418723160c5.webp",983,1305,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c4025c5602d63bda8bd1fb30eb18d984.webp",982,1304,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d28d612568b0a938b6cd4c3a64c05e33.webp",981,1303,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/75e787e3cda4e7ac1e83489b0d1209c4.webp",980,1301]